Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient with Treatment-Related Neuroendocrine Prostate Cancer with Urinary Retention and Rectal Obstruction: A Case Report-Reference-Cited by-同舟云学术

Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient with Treatment-Related Neuroendocrine Prostate Cancer with Urinary Retention and Rectal Obstruction: A Case Report

Published:2024 Issue:3 Volume:67 Page:266-269
ISSN:1346-8049
Container-title:Yonago Acta Medica
language:en
Short-container-title:Yonago Acta Med.

Author:

Yasukawa Ryusei¹,Kawamoto Bunya¹,Muraoka Kuniyasu¹,Nakamura Kazuhiko²,Honda Masashi³,Takenaka Atsushi³

Affiliation:

1. Department of Urology, Tottori Prefectural Central Hospital, Tottori 680-0901, Japan

2. Department of Radiology, Tottori Prefectural Central Hospital, Tottori 680-0901, Japan

3. Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8503, Japan

Publisher

Tottori University Faculty of Medicine

Link

https://www.jstage.jst.go.jp/article/yam/67/3/67_2024.08.010/_pdf

Reference11 articles.

1. 1. Eule CJ, Hu J, Al-Saad S, Collier K, Boland P, Lewis AR, et al. Outcomes of second-line therapies in patients with metastatic de novo and treatment-emergent neuroendocrine prostate cancer: a multi-institutional study. Clin Genitourin Cancer. 2023;21:483-90. PMID:37193610, DOI:10.1016/j.clgc.2023.04.008

2. 2. Deorah S, Rao MB, Raman R, Gaitonde K, Donovan JF. Survival of patients with small cell carcinoma of the prostate during 1973–2003: a population‐based study. BJU Int. 2012;109:824-30. PMID:21883857, DOI:10.1111/j.1464-410X.2011.10523.x

3. 3. Patel GK, Chugh N, Tripathi M. Neuroendocrine differentiation of prostate cancer-an intriguing example of tumor evolution at play. Cancers (Basel). 2019;11:1405. PMID:31547070, DOI:10.3390/cancers11101405

4. 4. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21:1067-1096. DOI:10.6004/jnccn.2023.0050

5. 5. Kim K, Kim SJ. Lu-177-based peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Nucl Med Mol Imaging. 2018;52:208-15. PMID:29942399, DOI:10.1007/s13139-017-0505-6